However, sensitivity (the proportion of patients with P/LP variants who were successfully identified) was only 0.20 for BRCA1/2-positive male individuals, compared with 0.38 for BRCA1/2-positive female individuals, and incorporating a personal history of cancer as an inclusion criterion reduced NNT for female individuals but not for male individuals. This evidence concerns the gene BRCA1 and cancer.